Exhibit 10.6 MediWound Ltd. and Challenge Bioproducts Corporation Ltd. Supply Agreement As amended on February 28, 2010 Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. SUPPLY AGREEMENT This Supply Agreement (“Agreement”) was made and entered into as of the 11 day of January, 2001 by and between MediWound Ltd., acorporation organized and existing under the laws of Israel (hereinafter referred to as “MediWound”) and Challenge Bioproducts Corporation Ltd., acorporation organized and existing under the laws of the Republic of China (hereinafter referred to as “CBC”) and amended by the parties onFebruary 28, 2010 (“Amendment Effective Date”). WITNESSETH: THAT Whereas MediWound and CBC have originally entered into this Agreement on the date stated above (copy of which shall be attached hereto asExhibit A); and Whereas, the parties hereto have agreed to amend and add certain terms and conditions to this Agreement as of the Amendment Effective Date, allas set forth and marked herein; and Whereas, CBC has invented and developed methods, processes and equipment to manufacture, and produce Bromelain SP (as such term is definedbelow), specially processed for transformation into a Bromelain-based pharmaceutical product derived from pineapple stems, known as Debridase(the “Product”); and Whereas, subject to the going into effect of a License Agreement dated September 27, 2000 between MediWound and Mark Klein (respectively,the “Klein Agreement” and “Klein”) as amended on June 19, 2007, MediWound shall have an exclusive license under patents and otherintellectual property, to develop, use, manufacture, market and sell the Product for burn treatment in humans; and Whereas, MediWound desires to utilize Bromelain SP in the development and commercialization of the Product and to subsequently purchaseBromelain SP in bulk form to make and have made Product and pharmaceutical preparations thereof; and Whereas, CBC is willing to supply Bromelain SP to MediWound for such purpose on the terms and conditions set forth hereunder. NOW THEREFORE IN CONSIDERATION OF THE MUTUAL PROMISES AND COVENANTS SET FORTH HEREIN IT IS HEREBY AGREEDAS FOLLOWS: Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 2 1. Definitions Terms defined in this Section 1 and elsewhere, parenthetically, in this Agreement, shall have the same meaning throughout thisAgreement. 1.1 “Affiliate” means any firm, person or company which controls, is controlled by or is under common control with a party to thisAgreement and for the purpose of this definition the term “control” means the possession, directly or indirectly of the power todirect or cause the direction of the management and policies of such firm, person or company whether through the ownership ofvoting securities, by contract or otherwise or the ownership either directly or indirectly of 20% (twenty percent) or more of thevoting securities of such firm, person or company. 1.2 “Approval” means the grant of all necessary governmental and regulatory approvals required for the marketing, distribution and sale ofa pharmaceutical product in any particular country, by a Regulatory Authority, and approvals required for pricing andreimbursements (if appropriate). 1.3 “Bromelain SP” means material derived from pineapple stems, [having the specification as presented in exhibit 1.13] presentlymanufactured by CBC at the Facility by a special process and used as a raw material in the production of the Product. 1.4 “Conditions Precedent” means the cumulative conditions listed in Section 2.1. 1.5 “Effective Date” shall have the meaning ascribed to such term in Section 2.2. 1.6 “Facility” means CBC’s production facility in Tou-Liu City, Yun-Lin Hsien, Taiwan, R.O.C. 1.7 “FDA” means the Food and Drug Administration of the United States Government or any successor thereto. 1.8 “Klein” means Mr. Mark C. Klein. 1.9 “LR” means either or both of L.R. R D Ltd. and/or Professor Lior Rosenberg. 1.10 “Major Country” means the USA, and the major European and Asian countries listed in Exhibit 1.10 attached hereto. 1.11 “MOU” means the Memorandum of Understanding of January 18, 2000 between MediWound (as assignee of Clal BiotechnologyIndustries Ltd.), Klein and CBC. 1.12 “Regulatory Authority” means the FDA or similar governmental or other agency in any country having authority to grant Approval. 1.13 “Specifications” means the specifications for Bromelain SP set forth as Exhibit 1.13 hereto, as the same may be amended with theconsent of both parties hereto, it being agreed that no amendment may be made thereto or refused which would Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 3 render Product incapable of application on humans or the use, supply or sale thereof in breach of any regulations. 1.14 “Sub-Contractor” means any firm or company whose services are retained by MediWound to transform Bromelain SP into Productand to package, label and deliver pharmaceutical preparations of the Product in finished form to MediWound and its sub-licensees. All references to “MediWound” under Sections 3.1, 5, 6 and 7.1 shall be construed as being inclusive of Sub-Contractors, unless the context dictates otherwise. 1.15 “Technical Information” means that information in use at the Facility during the term of this Agreement, relating to the manufacture ofBromelain SP meeting the Specifications, in bulk, as more comprehensively described in Section 1.15 of the TT Agreement. 1.16 “TT Agreement” means the Technology Transfer Agreement dated January 11, 2001 between the parties hereto, whereby CBCundertakes to transfer the Technical Information to MediWound. 2. Conditions Precedent 2.1 Conditions Precedent to the provisions of this Agreement becoming effective shall be all of the following: 2.1.1 Execution of a License Agreement between MediWound and LR whereby MediWound shall license certain Product-relatedknow-how from LR; and 2.1.2 Execution of the TT Agreement. 2.2 The date upon which MediWound shall have acknowledged in writing to CBC that the Conditions Precedent have all been met shall bethe “Effective Date”. Where the Conditions Precedent have not been met by January 31, 2001, for any reason whatsoever, thenthis Agreement and the MOU shall be deemed terminated as of that date with no further liability of either party, except for theobligation of confidentiality, as set forth in the MOU. 3. Grant of Rights 3.1 As from and subject to the Effective Date, and subject to the terms and conditions of this Agreement, CBC shall supply Bromelain SPto MediWound and MediWound shall acquire Bromelain SP from CBC, for transformation into the Product. 3.2 MediWound’s rights as per Section 3.1 will be exclusive in the sense that CBC shall not nor shall permit any Affiliate or third party tomanufacture, use, supply Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 4 or sell Bromelain SP for utilization as an ingredient of any product which directly or indirectly competes with the Product. 4. Financial Provisions 4.1 In consideration for CBC’s undertaking to supply Bromelain SP to MediWound and other obligations of CBC pursuant to thisAgreement, MediWound has paid to CBC US [] (US Dollars []) within 3 (three) business days of the Effective Date. 4.2 Payments for supply of Bromelain SP by CBC to MediWound as of the Amendment Effective Date shall be made in accordance with thefollowing provisions: 4.2.1 The price of [] Kg of an accepted batch of Bromelain SP (by MediWound pursuant to Section 6.4) shall be in accordancewith the price per annual quantity table in Exhibit 4.2 attached hereto. The price used for invoicing during the year shallbe based on the quantity in the Annual Forecast. At the end of each year the parties shall recalculate the amounts to bepaid pursuant to the actual quantities purchased throughout the passing year and adjust the payments accordingly (forexample: if the actual quantity purchased during the past year was higher than the Annual Forecast and such higherquantity should have been invoiced as per a lower price per Kg of Bromelain SP in accordance with price per annualquantity table in Exhibit 4.2, CBC shall recalculate the invoices for the past year as per the actual price that shouldhave been invoiced and credit MediWound for the balance within [] days accordingly. If the actual quantitypurchased during the past year was lower than the Annual Forecast and such lower quantity should have beeninvoiced as per a higher price per Kg of Bromelain SP in accordance with price per annual quantity table in Exhibit4.2, CBC shall recalculate the invoices for the past year as per the actual price that should have been invoiced andinvoice MediWound for the balance within [] days accordingly). 4.2.2 CBC may increase the prices only pursuant to an increase in its cost of manufacturing of the Bromelain SP. Any suchincrease shall be subject to MediWound’s pre-approval, and no increase shall be executed more often than once every[] months and any changes thereto shall be in-line with current market prices for Bromelain manufacturing exceptthat (i) there is a change of cost of manufacturing of Bromelain SP due to a change requested by regulatory agency andconfirmed by MediWound; and (ii) the Taiwan official Wholesale Price Index varies over []% within [] months.When such exceptional situations arise, an increase Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 5 of price shall be considered by MediWound at CBC’s written request without the limit of no more often than once every[] months. 4.2.3 MediWound shall make payment for each Bromelain SP batch that was supplied by CBC on a [] days basis as of the dateof delivery of the applicable batch at MediWound, provided that MediWound has provided CBC with an AcceptanceBatch Notice for such purchased batch pursuant to Section 6.4. Payment for each purchase batch shall be effected byMediWound by swift to a bank account designated by CBC, or by other requested method as agreed between theparties. MediWound shall make down payment of USD[]/kg for the []% of the amount of Annual Forecast beforeDec.31 of the respective year for the insurance of components and materials and maintenance of manufacture andsupply capacity of the requested []% of the next calendar year’s Annual Forecast. The down payment will be thendeducted respectively as every shipment is made to MediWound and listed in CBC’s Invoice to MediWound. 4.2.4 Payment shall be made directly to CBC for payment for each order of Bromelain SP or, at CBC’s written request, to GoldenLife International Co., Ltd. on CBC’s behalf, for payments other than any order of Bromelain SP (“Payee”); providedhowever, that any such payment to the Payee shall be considered as valid payment to CBC (as if made directly to CBC)in accordance with this Agreement, and that so long as such payment is made in accordance with CBC’s said request,CBC shall have no claims or demands against MediWound for non-payment or in any other respect whatsoever in thisregard. CBC solely shall be responsible to ensure that payment by MediWound to the Payee pursuant to CBC’s requestdoes not violate any applicable laws and regulations. Any tax implications due to payment to the Payee in accordancewith CBC’s request shall be borne by CBC. For avoidance of doubt, it is clarified that the Payee shall not be consideredas a third party beneficiary under this Agreement and shall not have any rights to enforce payment or any other rightsof CBC under this Agreement. 4.2.5 Invoices shall only be issued upon delivery of the Bromelain SP batch which shall take place only after CBC’s quality controldepartment has completed its testing and authorized delivery to MediWound, and MediWound’s quality controldepartment has provided CBC with an Acceptance Sample Notice for that batch and that the batch itself can bedelivered. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 6 4.2.6 The consideration to be paid pursuant to this Agreement is final and inclusive of all taxes and/or duties, of whatsoevernature. If applicable laws require the withholding of taxes, MediWound will deduct the taxes from the related paymentotherwise due to CBC, and such taxes shall be paid to the proper taxing authority. For avoidance of doubt, payments willbe made only after receiving exemption from tax deduction approval from the tax authority in Israel. Delay in payment asa result of not receiving such exemption will not constitute late payment or breach hereunder. 5. Manufacture of Bromelain SP 5.1 Without derogating from CBC’s representations and warranties herein, CBC and MediWound shall work together in order to enable theCBC facility to accomplish all required standards, related to the manufacturing, packaging and delivering of Bromelain SP inaccordance with the Specifications, GACP (Good Agricultural and Collection Practice) and cGMP (Current Good ManufacturingPractice) standards, ISO 22000 and all other applicable laws and regulations. For such purpose, and without derogating fromother terms herein, CBC shall permit MediWound, and/or a consultant on MediWound’s behalf, to access and inspect the CBCfacility and advise MediWound and/or CBC on such actions to be taken for accomplishing such compliance. Such mutualregulatory preparations shall begin no later than the finalization of MediWound’s current phase III clinical trial. CBC warrants and represents that all Bromelain SP shall be manufactured and supplied in compliance with the Specifications,quality control methods and test methods, all applicable SOP’s and all applicable laws, and in accordance with GACP, cGMP,including the relevant guidelines, policies, codes, requirements, regulations, approvals and/or standards from time to timepromulgated or issued by any relevant governmental and/or regulatory authority which relate to the manufacture of theBromelain SP to be used for the production of a pharmaceutical agent as the Product. CBC warrants further that CBC has, and will for the duration of this Agreement retain, all applicable regulatory approvals requiredfor the carrying out of its obligations hereunder, including without limitation the manufacturing, packaging and supply of theBromelain SP. 5.2 All manufacturing, packaging and labeling activities done at CBC will be performed according to the pre-approved batch records. IfCBC wishes to make changes to the Specifications, the production and/or packaging batch records, the SOPs related to theBromelain SP, or the design of the manufacturing process or any other change during production which would effect the qualityof the Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 7 Bromelain SP or of the Product and/or otherwise would effect the Bromelain SP in any way or which might effect the regulatoryapprovals of the Product, then CBC shall (i) notify MediWound in writing at least 6 months in advance regarding such proposedchanges, and (ii) represent that such change will not adversely effect the quality of the Bromelain SP or of the Product in anyway, and (iii) not make such changes without MediWound’s prior written approval, and (iv) will assure that such change will notdelay or in any way effect any open orders for Bromelain SP. 5.3 MediWound shall participate and support the upgrade of the Facility and the generation of documentation for submission to therelevant Regulatory Authorities, all as may be determined to be necessary and appropriate, by independent regulatoryconsultants, designated by mutual consent. Such participation and support shall be in the form of an investment made byMediWound in the CBC facility, not to exceed [] (US Dollars []). 5.4 CBC undertakes to keep all records reasonably required by MediWound relating to the manufacture, quality control and testing ofBromelain SP. Such records shall include, but not be limited to, all records required by applicable laws and regulations, of theterritories in which the Product is marketed and sold. MediWound (itself or through anyone on its behalf) or any relevantregulatory authority shall have the right to audit any such records and/or the relevant facilities of CBC (or any facilities of anyCBC third party or subcontractor involved in the manufacture, quality control and/or supply of the Bromelain SP) with reasonableprior notice, during regular business hours, including the right to ask CBC to provide any relevant documents. CBC shall informMediWound of any announced regulatory inspections that directly involve the Bromelain SP or the Product within 48 hours ofthe notification to CBC of such an inspection. 5.5 During the term of this Agreement, CBC shall make available to MediWound any and all information and data which it generates orwhich comes into its possession relating to any improvements in the manufacture and supply of the Bromelain SP. CBC shall,throughout the term of this Agreement, assist MediWound in all respects with regard to regulatory submission including but notlimited to providing any information, data or documents in its possession. If any regulatory agency requests any changes to theSpecifications or the manufacturing process, (including but not limited to any changes as a result of an audit performed) CBCshall (i) inform MediWound in advance and in writing of the changes needed to be made, and (ii) promptly advise MediWoundas to any lead-time changes or other terms which may result therefrom, and (iii) make such changes, in coordination withMediWound as soon as possible. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 8 5.6 Sampling and Testing Procedures 5.6.1 The sampling procedures of incoming raw materials, packaging materials, in process control and released Bromelain SP shallbe agreed between CBC and MediWound and conducted by CBC as per CBC’s signed SOP as approved byMediWound. 5.6.2 MediWound and CBC will jointly agree and update from time to time as applicable the incoming raw materials, in-processand release testing methods applicable to the Bromelain SP. 5.6.3 CBC will test each batch of Bromelain SP for conformance with the batch Specifications, and for each batch of the BromelainSP supplied by CBC, CBC will provide a certificate of analysis signed and dated by the responsible person at CBC, whohas released the batch. 5.6.4 For each batch provided, CBC shall provide to MediWound a copy of the batch production and packaging executionrecords and shall retain such original records for one (1) year beyond the shelf-life of the Bromelain SP unless requiredby MediWound or under applicable laws and regulations to maintain the records for a longer period of time. 5.7 Quality Assurance Investigations 5.7.1 Any deviation from the production process during the manufacture thereof shall be explained and documented in batchrecords. Any deviation that may impact on the safety/quality of the Bromelain SP or the Products and on other relatedissues will be investigated by CBC, and communicated to MediWound within 48 hours from the time of discovery.Following the investigation, the relevant corrective actions shall be taken and implemented. 5.7.2 CBC shall perform an out-of-specifications investigation in respect of batches that do not meet the batch Specifications. 5.7.3 Each investigation shall be reviewed by a CBC designated quality representative, and will follow the proceduresrecommended by regulatory agencies and as set out in relevant CBC SOP’s. All completed investigation reports andother written documentation relating to all investigations shall be provided to MediWound and shall be included in theapplicable released and executed batch records. Any corrective actions shall be discussed and agreed by the partiesbefore being executed by CBC. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 9 5.8 Quality Complaints; Recall 5.8.1 MediWound and CBC shall notify each other immediately by an e-mail, of any information concerning the quality and/ormalfunction of the Bromelain SP. The parties will investigate all complaints, and shall respond in accordance withmutually agreed SOP’s. Both parties shall comply with requirements of all regulatory authorities in dealing withcomplaints. MediWound shall have the right to determine whether any adverse event should be reported to anyapplicable regulatory authority. All quality assurance and/or quality complaints shall be handled in accordance with thissection above. 5.8.2 In the event that CBC has any reason to believe that the Bromelain SP or one or more Products should be recalled orwithdrawn from distribution, CBC shall immediately notify MediWound in writing. In such event MediWound shall, atMediWound’s sole discretion, determine whether to recall or withdraw the Product from the market. 5.8.3 If a recall of the Product is due to CBC or the Bromelain SP, then the recall shall be conducted by MediWound at CBC’sexpense, and CBC shall replace such Bromelain SP at no charge to MediWound or shall provide MediWound with acredit or refund of same, at MediWound’s election. 5.9 Storage CBC shall store, in accordance with the applicable CBC SOP, free of charge, Bromelain SP batches at its premises in appropriatestorage conditions, for up to ninety (90) days from the day of the Acceptance Sample Notice for the respective batch or longer ifCBC was unable to deliver such batch to MediWound earlier following the Acceptance Sample Notice. The Bromelain SP shelflife and designated packaging shall be in accordance with CBC SOP and subject to the supportive results of a proper stabilitystudy. 5.10 Retention of Samples CBC shall retain samples of Bromelain SP stored at their original package from each batch for the duration of the Products’ shelf-life and for a period of one (1) additional year thereafter, in quantities sufficient to enable the performance of two (2) CBC’s fullrelease tests in accordance with the CBC’s release specifications and release methods. 6. Supply of Bromelain SP 6.1 MediWound undertakes to purchase, and CBC undertakes to furnish, supply and deliver Bromelain SP to MediWound, in bulk, on theterms and conditions hereinafter set forth. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 10 6.2 MediWound shall furnish CBC with a non-binding forecast of its anticipated annual requirements of Bromeline SP by no later thanNovember 1 of each year (“Annual Forecast”), for the next calendar year. Notwithstanding the foregoing, the first forecast for thecalendar year that commenced on January 1, 2001, was furnished by MediWound to CBC by March 15, 2001. MediWoundundertakes to order at least []% of the Annual Forecast per each year. CBC shall maintain, at all times, manufacture and supply capacity of at least []% of the Annual Forecast and shall maintain, incoordination with MediWound, inventory of Bromelain SP at its premises of (i) at least []% of the applicable AnnualForecast; and (ii) all Bromelain SP components and materials (“the BSP Components and Materials”) needed for the manufactureand supply of the Bromelain SP such that CBC can guarantee continuous supply of the Bromelain SP in accordance withMediWound’s complete Annual Forecasts. In addition, the inventory of the BSP Components and Materials shall not be lessthan needed to manufacture [] months stock of Bromelain SP (compared to the open purchase orders and the applicableAnnual Forecast) or longer (respectively) for BSP Components and Materials having a lead time of more than [] months. CBCshall provide MediWound with quarterly inventory and production reports for Bromelain SP and BSP Components and Materials. Purchase orders issued by MediWound to CBC for quantities within the []% of the Annual Forecast shall be binding uponCBC and shall be deemed accepted upon delivery of the purchase order to CBC. Such purchase orders shall be supplied on thedate specified in the applicable purchase order provided that the lead time in any purchase order shall be at least [] days as ofthe purchase order’s date. Purchase orders issued by MediWound to CBC during a certain year for quantities exceeding []% of the applicable AnnualForecast shall be binding upon CBC, except that with respect to any amounts exceeding []% of the applicable AnnualForecast, CBC’s obligation to provide such exceeding quantities shall be based on best efforts and CBC shall have an extendedlead time for delivery as shall be agreed upon by the parties on a case by case basis. CBC shall confirm in writing, within 5 daysof its acceptance of such exceeding purchase order, and shall state the anticipated delivery date for the exceeding amounts. Without derogating from CBC’s obligations under this Agreement, in the event that CBC is unable to supply all the Bromelain SPcovered under any purchase order on the dates specified in the applicable supply plans, CBC shall promptly notify MediWoundin writing in a separate notice to MediWound of such delay or noncompliance. In such event, and without prejudice to any otherremedies Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 11 available to MediWound, CBC shall use its best efforts to fully comply with the purchase order as soon as possible. 6.3 CBC shall be responsible to prepare the shipment of Bromelain SP in accordance with a shipment SOP. Such shipment SOP shall complywith the regulatory requirements as well as specify the documents that should accompany any shipment (i.e. pro forma invoice,value for customs, specific declaration, and specific requirement for investigational products). CBC shall provide MediWoundwith copies of documents and reports with respect to each shipment of Bromelain SP, for quality assurance, quality control andregulatory purposes. 6.4 Prior to delivery of each batch of Bromelain SP, CBC shall submit a batch sample to MediWound for inspection and approval.MediWound shall have the right, for a period of [] days following receipt, to reject any Bromelain SP sample which: 6.4.1 fails to comply with MediWound’s purchase order; or 6.4.2 fails to comply with the sample incoming inspection Specifications. Within the said [] days, MediWound shall notify CBC of either: (i) its approval and acceptance of such batch sample(“Acceptance Sample Notice”); or (ii) its rejection of the batch sample in which case MediWound shall detail the reason(s) for therejection of any such Bromelain SP sample. In the event of rejection by MediWound, CBC shall deliver complying Bromelain SPsample to MediWound within [] days of rejection, free of cost (including transportation, duty, handling and insurance costs).For clarification purposes, MediWound’s Acceptance Sample Notice in accordance with this section above shall in no eventderogate from CBC’s responsibilities hereunder. After CBC receives MediWound’s Acceptance Sample Notice, CBC shall deliver the corresponding batch to MediWound forinspection and approval. MediWound shall have the right, for a period of [] days following receipt, to reject any Bromelain SPbatch which: 6.4.3 fails to comply with MediWound’s purchase order; or 6.4.4 fails to comply with the batch incoming inspection Specifications. Within the said [] days, MediWound shall notify CBC of either: (i) its approval and acceptance of such batch (“AcceptanceBatch Notice”); or (ii) its rejection of the batch in which case MediWound shall detail the reason(s) for the rejection of any suchBromelain SP batch. In the event of rejection by MediWound, at CBC’s request and expense, MediWound shall return any suchBromelain SP batch to CBC and CBC shall deliver complying Bromelain SP Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 12 batch to MediWound within [] days of rejection, free of cost (including transportation, duty, handling and insurance costs).For clarification purposes, MediWound’s Acceptance Batch Notice in accordance with this section above shall in no eventderogate from CBC’s responsibilities hereunder. 6.5 If there is a dispute between the parties as to whether any Bromelain SP sample or batch complies with the sample or batchSpecifications respectively and/or with the quality requirements set forth herein and/or under the law, then, without derogatingfrom MediWound’s remedies under this Agreement or at law, such dispute shall be resolved by mutual investigation of theparties which shall be conducted in good faith. If the parties are still unable to resolve such dispute, an independent, mutuallyagreed third party shall be retained as a consultant to review batch records and related documentation. Such consultant’sdetermination in respect of the conformity of a sample or batch shall be binding upon the parties. The non-prevailing party shallbear the costs of consultant’s services as well as for the production of the batch and corrective actions. If appropriate, pursuantto such investigation and/or consultant’s determination, CBC shall replace the non-complying Bromelain SP within 30 (thirty)days thereafter, free of cost (including transportation, duty, handling and insurance costs). 6.6 CBC, at its own cost, shall obtain and shall cause to remain in effect, such licenses, permits, approval and consents as may be requiredfor its performance hereunder, including, without limitation, export of Bromelain SP from the Republic of China. 7. Liability and Indemnity 7.1 CBC shall defend and assume responsibility for any suit, claim or other action by a third party alleging that MediWound’s use ofBromelain SP infringes any patents or other rights of such third party. 7.2 MediWound shall be solely responsible for the commercialization of the Product, e.g. the completion of development, final formulation,the conduct of clinical trials (as necessary), labeling and packaging, as well as the due preparation and submission of alldocumentation required for the prosecution of registration and Approval of the Product in each of the countries in the Territory.MediWound shall assume all liabilities arising from the development, commercialization, use, offer for sale, sale or supply by,through or on behalf of MediWound or its Affiliates, of the Product (and related materials). 7A. Insurance In order to provide insurance coverage for CBC responsibilities, obligations and undertakings as set out under this Agreement and/or asrequired under any law with Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 13 respect to the manufacturing of Bromelain SP, CBC undertakes, at its sole cost and expense, to take out and maintain an “All risk”insurance against loss of and destruction or damage to the Facility (including fire, theft and vandalism, etc.), third party liability insurance,product liability insurance for the Bromelain SP and employers liability insurance. Without prejudice to the above, CBC shall maintain, or shall cause to be maintained with respect to itself and each of its Affiliates, suchtypes and levels of insurance (including, without limitation, third party and product liability insurance), as are customary in thepharmaceutical or manufacturing industry to provide coverage for their activities contemplated hereby. Upon request of MediWound,CBC shall keep MediWound informed of the general parameters of its liability insurance program and any proposed substantive changestherein. Upon request, CBC shall furnish MediWound certification of insurance (and/or true copies of policies) showing the abovecoverage, signed by an authorized agent of the insurance company, certifying that liability assumed under this Agreement is fully insuredwithout exception, and providing for at least thirty (30) days prior written notice. 7B. Limitation of Consequential Damages EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATION HEREUNDER, AND TO THE EXTENT PERMITTED BY APPLICABLELAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIALDAMAGES, INCLUDING WITHOUT LIMITATION LOSS OF USE, DATA OR LOST PROFITS, EVEN IF IT HAS BEEN ADVISED OFTHE POSSIBILITY OF SUCH DAMAGES, WHETHER UNDER THIS AGREEMENT, IN TORT OR OTHERWISE. 8. Confidentiality 8.1 CBC and MediWound undertake to each other to keep, and shall procure that their respective Affiliates, employees, directors, officers,consultants and contractors (including those of any Affiliate) shall keep, confidential all information received from each otherduring or in anticipation of this Agreement however obtained and in whatever form (the “Confidential Information”). Forclarification purposes, any information, materials and know-how related to the Product and/or provided by MediWound inconnection with this Agreement including any related intellectual property rights, shall be owned solely by MediWound andshall constitute MediWound’s Confidential Information which may be used by CBC solely for the purpose of manufacturing andsupply of Bromelain SP to MediWound. Confidential Information shall not include the following: Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 14 8.1.1 information which at the time of disclosure by one party to the other is in the public domain; 8.1.2 information which after disclosure by one party to the other becomes part of the public domain by publication except bybreach of this Agreement; 8.1.3 information which the receiving party can establish by competent proof was already in its possession at the time of itsreceipt and was not acquired directly or indirectly from the other party; and 8.1.4 information received from third parties who were lawfully entitled to disclose such information. 8.2 Any Confidential Information received from the other party shall not be disclosed or used for any purpose other than as provided oranticipated under this Agreement. 8.3 The confidentiality and non-use obligations contained in this Agreement shall continue for the duration of this Agreement and for aperiod of 5 (five) years after termination or expiry of this Agreement, provided however that any Confidential Information withrespect to the Product, including without limiting, such information with respect to intellectual property rights in connection withand/or related to the Products shall remain confidential in perpetuity. 8.4 The provisions of this Section 8 shall in no event prevent MediWound from disclosing any Technical Information to RegulatoryAuthorities or other governmental agencies in support of any application for regulatory approvals of the Product or anyamendments thereof or in general whenever required to disclose such information under any applicable law or regulation.MediWound shall make reasonable efforts to notify CBC of its intention and the identity of the intended recipient as soon asreasonably practicable and if possible, prior to the date of disclosure. 9. Duration This Agreement shall come into force on the Effective Date and the amendments herein shall be in effect as of the Amendment EffectiveDate. This Agreement as amended shall continue in force until terminated in accordance with the provisions of Section 10. 10. Termination 10.1 MediWound may terminate this Agreement at any time, by 6 (six) months prior notice in writing. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 15 10.2 CBC may terminate this Agreement by no less than 24 (twenty four) months notice given in writing by CBC to MediWound, or suchgreater period as may be reasonable for MediWound to establish an alternative source of manufacture of Bromelain SP and/or toacquire sufficient inventory of Bromelain SP for a 24 (twenty four) months period. 10.3 In the event of any breach of this Agreement at any time, if the breach complained of shall not be corrected by the breaching partywithin 90 (ninety) days of the other party’s notice, either party hereto may, at its option: 10.3.1 by giving 90 (ninety) days written notice, specifying the breach complained of, terminate this Agreement, and the partyasserted to be in breach shall have the right to treat the alleged breach as a dispute under Section 15; or 10.3.2 regard the breach and any failure to cure as the basis for a dispute and proceed to dispute resolution under Section 15 andsuch legal or equitable remedy as shall be applicable. 11. Effects of Termination 11.1 Upon termination of this Agreement, the parties shall abide by and uphold any and all rights or obligations accrued or existing as ofthe termination date, including, without limitation with respect to outstanding orders for Bromelain SP placed hereunder. 11.2 Any rights or remedies of either party arising from any breach of this Agreement shall continue to be enforceable after termination ofthis Agreement, unless previously waived in writing. 12. Assignment 12.1 Subject to Section 12.2, neither party shall assign its rights or obligations hereunder, in whole or in part, except with the prior writtenconsent of the other party, except to a party acquiring all of the business of the assigning party to which this Agreement relates.Prior to any such permitted assignment the party wishing to effect the transaction shall procure that the third party concernedcovenants directly with the other party to this Agreement to comply with the provisions of this Agreement, which shall bebinding on it as the successor and assign of such party. 12.2 MediWound may assign all of its rights and obligations under this Agreement or perform some or all of its obligations under thisAgreement through its Affiliates and Sub-Contractors, provided that MediWound shall remain solely responsible for and beguarantor of the performance by its Affiliates and Sub-Contractors and Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 16 procure that its Affiliates and Sub-Contractors comply fully with the provision of this Agreement in connection with suchperformance. 13. Miscellaneous 13.1 Failure or delay by either party in exercising or enforcing any right or remedy under this Agreement in whole or in part shall not bedeemed a waiver thereof or prevent the subsequent exercise of that or any other rights or remedy. 13.2 CBC and its employees and MediWound and its employees shall at all times be considered as independent contractors of each other,and at no time or under any circumstances shall they be considered employees, representatives, partners or agents of each other. 13.3 This Agreement shall constitute the entire agreement and understanding of the parties relating to the subject matter of this Agreementand supersede all prior oral or written agreements, understandings or arrangements between them relating to such subject, exceptfor the TT Agreement. The MOU shall be deemed so superseded by this Agreement only upon the Effective Date. 13.4 Other than as explicitly amended and marked herein, all applicable terms and conditions of the Agreement as originally executed by theparties shall remain without change and shall continue to be binding and in full force and effect. No change or addition may bemade to this Agreement except in writing signed by the duly authorized representatives of both parties. 13.5 The provisions intended by their nature to survive the termination or expiration of this Agreement shall so survive including withoutlimiting Sections 1, 3.2, 5.1, 5.2, 5.4, 5.8, 5.10, 7, 7A, 7B, 8, 11, 13 (as amended), 14 and 15. Without derogating from the foregoing, it is clarified that the restriction with respect to MediWound’s intellectual property andCBC’s obligations under the TT Agreement as well as MediWound’s exclusive rights under this Agreement (as amended) shallcontinue to apply and survive the termination or expiration of the Agreement. 14. Notices 14.1 Any notice or other document given under this Agreement shall be in writing in the English language and shall be given by hand orsent by prepaid airmail, by facsimile transmission or electronic mail to the address of the receiving party as set out below unless adifferent address, facsimile number or e-mail address has been notified to the other in writing for this purpose. 14.2 MediWound’s address for service of notices and other documents shall be:- Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 17 MediWound Ltd.42 Hayarkon St., 81227 Yavne IsraelTel: 972 8 932 4010Fax: 972 8 932 4011E-Mail: [] 14.3 CBC’s address for service of notices and other documents shall be:- Challenge Bioproducts Corporation, Ltd.17 Tou-Kong 12 Rd., Tou-Liu City, Yun-Lin Hsien,Taiwan, R.O.C., (“CBC”)Facsimile: 55-5572-045E-Mail: [] 15. Governing Law and Disputes 15.1 This Agreement is made under and subject to the provision of the substantive laws of the State of New York, without giving effect toits conflict of law rules. 15.2 Any disputes relating to this Agreement of whatever nature that cannot be resolved by negotiation between the parties shall bereferred for final resolution to arbitration in New York City by 3 (three) Arbitrators under the Rules of the American ArbitrationAssociation. The arbitration proceedings shall be conducted in English. The decision of the arbitrators shall be final and bindingupon the parties and their legal successors. The arbitrators may at their discretion, provide for discovery by the parties not toexceed 4 (four) months from the date of notice of arbitration and the arbitrators shall notify the parties of their decision in writingwithin 30 (thirty) days of the completion of the final hearing. The arbitrators may at their discretion award costs and expenses inrespect of the arbitration. 15.3 The parties submit to the exclusive jurisdiction of the courts of the State of New York. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 18 IN WITNESS WHEREOF, the parties, each by its duly authorized signatory, have caused this Agreement to be executed as of the date first above-mentioned. /s/ Gal Cohen /s/ Ching-Kuan Lin MediWound Ltd. Challenge Bioproducts Corporation Ltd. By: Gal Cohen By: Ching-Kuan Lin Its: Chief Executive Officer Its: President MediWound Ltd. Challenge Bioproducts Co., Ltd. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 19 List of Exhibits Exhibit 1.13 - Current Bromelain SP Specifications Exhibit 4.2 - Price list per annual quantity Exhibit A - a copy of this Supply Agreement as originally signed on 11/1/2001 Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 20 Exhibit 1.13 Current Bromelain SP Specifications [] Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. Exhibit 4.2 Price list per annual quantity MediWound Ltd.42 Hayarkon Street, Yavne, IsraelTel: 972-8-9324010www.mediwound.com Supply Agreement as amended on Feb 28 2010. Exhibit 4.2 Price list per annual quantity The price of []Kg of released BSP below an annual ordered quantity of [] Kg shall be USD[]/Kg []. The price of []Kg of released BSP above an annual ordered quantity of [] Kg shall be between USD[]/Kg [], as jointly agreed and setbetween CBC and MW, once the forecasted annual ordered quantity exceeds [] Kg of released BSP. Challenge Bioproducts Corporation Ltd: Date: 2011.10.12 Signature: /s/ Ching-Kuan Lin MediWound Ltd. Date: Signature: /s/ Gal Cohen Chief Executive Officer MediWound, Ltd. Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. th Exhibit A - a copy of this Supply Agreement as originally signed on 11/1/2001 [Omitted: Agreement no longer in effect] Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentialityrequest. Omissions are designated as []. A complete version of this exhibit has been provided separately to the Securities and ExchangeCommission. 1